Physiomics Regulatory News (PYC)

Physiomics plc

("Physiomics") or ("the Company")

Physiomics to present new developments of the Virtual Tumour platform and the drugCARD Database at Annual Meeting for American Association for Cancer Research ("AACR")

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center, Washington, DC on 6-10 April 2013. Dr Frances Brightman and Dr Eric Fernandez will present respectively on the application of the Virtual Tumour platform to radiotherapy prediction and on the latest developments of the drugCARD database.

We have initiated a number of programmes to extend the capabilities of the Virtual Tumour™ model. The results presented in the first poster illustrate how the Virtual Tumour™ model can be employed to simulate tumour growth response to irradiation and the capability of this model to predict therapeutic efficacy of combinations involving irradiation and chemotherapy.

DrugCARD a new database of anti-cancer drugs and therapeutic treatment information is the result of collaboration between Physiomics and Pharmacometrics. In the second poster we

will demonstrate how it can researchers and clinicians rapidly access and search pre-clinical and clinical drug regimen data. The database is in the final stages of development and will be launched soon.

The abstracts ("Modeling ionizing radiation exposure in vitro and in vivo using the Virtual Tumour", No 5233 and "drugCARD: a database of anticancer treatment regimens and drug combinations", No 5147) will be presented respectively in the "Integrative and Computational Cancer Biology" and in the "Bioinformatics Algorithms, Models, and Tools" poster sessions, both scheduled 8:00 AM - 12:00 PM, 10 April 2012.

More information about the conference may be found at:

http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2013.aspx

Dr Mark Chadwick, CEO of Physiomics, commented:

"The new developments on our Virtual Tumour platform demonstrate our commitment to applying the technology across all possible cancer therapies. Work on radiation combinations has already been applied to commercial projects. We are also pleased to present our progress on the drugCARD database, which is now close to launch."

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002